J Med Life Sci.  2023 Jun;20(2):89-93. 10.22730/jmls.2023.20.2.89.

Consideration of fractionation or field size prior to radiation therapy in patients with breast cancer and psoriasis: a case report

• Hyun JY
• Park SH
• Kim DH
• Choi J

• KMID: 2561933
• DOI: http://doi.org/10.22730/jmls.2023.20.2.89

Abstract

We present three cases of patients with breast cancer and psoriasis who received radiotherapy following breast-conserving surgery. One patient developed an extensive flare-up of psoriasis during chemotherapy. After discontinuing chemotherapy, she received conventional radiotherapy to the ipsilateral whole breast, axillary, and supraclavicular lymph nodes with 50.4 Gy in 28 fractions and boosted with 10 Gy in five fractions to the tumor bed. Two patients received hypofractionated whole-breast radiotherapy at a total dose of 40.05–42.4 Gy in 15–16 fractions. In all three cases, there was no flare-up of psoriatic events at least 6 months after the completion of radiotherapy. We hypothesized that there is a close relationship between psoriatic events and the extent of trauma rather than the daily dose of the fraction. Therefore, we confirmed that the effect of radiotherapy on psoriatic events is minimal if the radiation field size does not exceed that of the whole breast.

Keyword

Breast neoplasms; Psoriasis; Radiotherapy; Skin; Toxicity